

Stephen Senn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6012626/publications.pdf>

Version: 2024-02-01

218
papers

11,141
citations

71061

41
h-index

39638

94
g-index

299
all docs

299
docs citations

299
times ranked

12175
citing authors

#	ARTICLE	IF	CITATIONS
1	A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2008, 359, 1543-1554.	13.9	1,969
2	Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. <i>European Journal of Epidemiology</i> , 2016, 31, 337-350.	2.5	1,761
3	Testing for baseline balance in clinical trials. <i>Statistics in Medicine</i> , 1994, 13, 1715-1726.	0.8	393
4	Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2337.	3.8	290
5	Change from baseline and analysis of covariance revisited. <i>Statistics in Medicine</i> , 2006, 25, 4334-4344.	0.8	267
6	Covariate imbalance and random allocation in clinical trials. <i>Statistics in Medicine</i> , 1989, 8, 467-475.	0.8	240
7	Individual response to exercise training - a statistical perspective. <i>Journal of Applied Physiology</i> , 2015, 118, 1450-1459.	1.2	204
8	Seven myths of randomisation in clinical trials. <i>Statistics in Medicine</i> , 2013, 32, 1439-1450.	0.8	177
9	Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design. <i>Statistics in Medicine</i> , 1994, 13, 197-198.	0.8	176
10	A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. <i>Clinical Therapeutics</i> , 2003, 25, 1295-1320.	1.1	163
11	Mastering variation: variance components and personalised medicine. <i>Statistics in Medicine</i> , 2016, 35, 966-977.	0.8	143
12	Some controversies in planning and analysing multi-centre trials. , 1998, 17, 1753-1765.		138
13	Overstating the evidence – double counting in meta-analysis and related problems. <i>BMC Medical Research Methodology</i> , 2009, 9, 10.	1.4	134
14	Individual response to treatment: is it a valid assumption?. <i>BMJ: British Medical Journal</i> , 2004, 329, 966-968.	2.4	130
15	Statistical pitfalls of personalized medicine. <i>Nature</i> , 2018, 563, 619-621.	13.7	129
16	Surveillance of antimicrobial resistance – what, how and whither?. <i>Clinical Microbiology and Infection</i> , 2001, 7, 316-325.	2.8	117
17	Measurement in clinical trials: A neglected issue for statisticians?. <i>Statistics in Medicine</i> , 2009, 28, 3189-3209.	0.8	115
18	Controversies concerning randomization and additivity in clinical trials. <i>Statistics in Medicine</i> , 2004, 23, 3729-3753.	0.8	109

#	ARTICLE	IF	CITATIONS
19	Repeated measures in clinical trials: simple strategies for analysis using summary measures. , 2000, 19, 861-877.		102
20	Trying to be precise about vagueness. <i>Statistics in Medicine</i> , 2007, 26, 1417-1430.	0.8	99
21	Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. <i>Pain</i> , 2014, 155, 1683-1695.	2.0	99
22	Power and sample size when multiple endpoints are considered. <i>Pharmaceutical Statistics</i> , 2007, 6, 161-170.	0.7	90
23	Two cheers for P-values?. <i>Journal of Epidemiology and Biostatistics</i> , 2001, 6, 193-204.	0.4	88
24	Disappointing dichotomies. <i>Pharmaceutical Statistics</i> , 2003, 2, 239-240.	0.7	82
25	Cross-over trials in <i>Statistics in Medicine</i> : the first 25 years. <i>Statistics in Medicine</i> , 2006, 25, 3430-3442.	0.8	81
26	Falsificationism and clinical trials. <i>Statistics in Medicine</i> , 1991, 10, 1679-1692.	0.8	77
27	Is the "simple carry-over" model useful?. <i>Statistics in Medicine</i> , 1992, 11, 715-726.	0.8	71
28	Fisher's game with the devil. <i>Statistics in Medicine</i> , 1994, 13, 217-230.	0.8	71
29	Consensus and Controversy in Pharmaceutical Statistics. <i>Journal of the Royal Statistical Society: Series D (the Statistician)</i> , 2000, 49, 135-176.	0.2	71
30	A comment on replication,p-values and evidence S.N.Goodman, <i>Statistics in Medicine</i> 1992;11:875-879. <i>Statistics in Medicine</i> , 2002, 21, 2437-2444.	0.8	70
31	Stratification for the propensity score compared with linear regression techniques to assess the effect of treatment or exposure. <i>Statistics in Medicine</i> , 2007, 26, 5529-5544.	0.8	69
32	Issues in performing a network meta-analysis. <i>Statistical Methods in Medical Research</i> , 2013, 22, 169-189.	0.7	62
33	Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials. <i>Statistics in Medicine</i> , 1994, 13, 293-296.	0.8	61
34	Early priribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. <i>Movement Disorders</i> , 2006, 21, 2110-2115.	2.2	61
35	Understanding Variation in Sets of N-of-1 Trials. <i>PLoS ONE</i> , 2016, 11, e0167167.	1.1	59
36	The AB/BA crossover: past, present and future?. <i>Statistical Methods in Medical Research</i> , 1994, 3, 303-324.	0.7	57

#	ARTICLE	IF	CITATIONS
37	Cross-over trials, carry-over effects and the art of self-delusion. <i>Statistics in Medicine</i> , 1988, 7, 1099-1101.	0.8	54
38	Statistical issues in bioequivalence. <i>Statistics in Medicine</i> , 2001, 20, 2785-2799.	0.8	53
39	The use of baselines in clinical trials of bronchodilators. <i>Statistics in Medicine</i> , 1989, 8, 1339-1350.	0.8	51
40	Hans van Houwelingen and the Art of Summing up. <i>Biometrical Journal</i> , 2010, 52, 85-94.	0.6	49
41	A personal view of some controversies in allocating treatment to patients in clinical trials. <i>Statistics in Medicine</i> , 1995, 14, 2661-2674.	0.8	46
42	Investigating variability in patient response to treatment – a case study from a replicate cross-over study. <i>Statistical Methods in Medical Research</i> , 2011, 20, 657-666.	0.7	46
43	Sample size considerations for <i>n</i> -of-1 trials. <i>Statistical Methods in Medical Research</i> , 2019, 28, 372-383.	0.7	43
44	Estimating Treatment Effects in Clinical Trials Subject to Regression to the Mean. <i>Biometrics</i> , 1985, 41, 555.	0.8	42
45	The first t-test. <i>Statistics in Medicine</i> , 1994, 13, 785-803.	0.8	42
46	Inherent difficulties with active control equivalence studies. <i>Statistics in Medicine</i> , 1993, 12, 2367-2375.	0.8	41
47	Statistical issues in first-in-man studies. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2007, 170, 517-579.	0.6	40
48	A Note Concerning a Selection – Paradox – of Dawid's. <i>American Statistician</i> , 2008, 62, 206-210.	0.9	40
49	Short-Term Acetylsalicylic Acid (Aspirin) Use for Pain, Fever, or Colds – Gastrointestinal Adverse Effects. <i>Drugs in R and D</i> , 2011, 11, 277-288.	1.1	38
50	Carry-over in cross-over trials in bioequivalence: theoretical concerns and empirical evidence. <i>Pharmaceutical Statistics</i> , 2004, 3, 133-142.	0.7	37
51	The graphical representation of clinical trials with particular reference to measurements over time. <i>Statistics in Medicine</i> , 1990, 9, 1287-1302.	0.8	36
52	Review of Fleiss, statistical methods for rates and proportions. <i>Research Synthesis Methods</i> , 2011, 2, 221-222.	4.2	35
53	Crossover trials, degrees of freedom, the carryover problem and its dual. <i>Statistics in Medicine</i> , 1991, 10, 1361-1374.	0.8	34
54	Ethical considerations concerning treatment allocation in drug development trials. <i>Statistical Methods in Medical Research</i> , 2002, 11, 403-411.	0.7	34

#	ARTICLE	IF	CITATIONS
55	SOME STATISTICAL ISSUES IN PROJECT PRIORITIZATION IN THE PHARMACEUTICAL INDUSTRY. , 1996, 15, 2689-2702.		33
56	Interpreting patient treatment response in analgesic clinical trials: Implications for genotyping, phenotyping, and personalized pain treatment. Pain, 2014, 155, 457-460.	2.0	33
57	Francis Galton and Regression to the Mean. Significance, 2011, 8, 124-126.	0.3	32
58	A note on non-parametric ANCOVA for covariate adjustment in randomized clinical trials. Statistics in Medicine, 2003, 22, 3583-3596.	0.8	31
59	Robust and realistic approaches to carry-over. , 1998, 17, 2849-2864.		30
60	The ghosts of departed quantities: approaches to dealing with observations below the limit of quantitation. Statistics in Medicine, 2012, 31, 4280-4295.	0.8	30
61	Investigating underlying risk as a source of heterogeneity in meta-analysis by S. G. Thompson, T. C. Smith and S. J. Sharp, Statistics in Medicine, 16, 2741-2758 (1997). , 1999, 18, 110-115.		29
62	Gastrointestinal Adverse Effects of Short-Term Aspirin Use: A Meta-Analysis of Published Randomized Controlled Trials. Drugs in R and D, 2013, 13, 9-16.	1.1	28
63	In the blood: proposed new requirements for registering generic drugs. Lancet, The, 1998, 352, 85-86.	6.3	27
64	Estimating treatment effects in clinical crossover trials. Journal of Biopharmaceutical Statistics, 1998, 8, 191-233.	0.4	27
65	Comment on article by Gelman. Bayesian Analysis, 2008, 3, .	1.6	26
66	Comparisons of minimization and Atkinson's algorithm. Statistics in Medicine, 2010, 29, 721-730.	0.8	26
67	Tea for Three: Of Infusions and Inferences and Milk in First. Significance, 2012, 9, 30-33.	0.3	26
68	Echocardiographic Evidence for Valvular Toxicity of Benfluorex: A Double-Blind Randomised Trial in Patients with Type 2 Diabetes Mellitus. PLoS ONE, 2012, 7, e38273.	1.1	26
69	Methods for assessing difference between groups in change when initial measurement is subject to intra-individual variation. Statistics in Medicine, 1994, 13, 2280-2285.	0.8	24
70	Defining drug response for stratified medicine. Drug Discovery Today, 2017, 22, 173-179.	3.2	24
71	Demonstrating Heterogeneity of Treatment Effects Among Patients: An Overlooked but Important Step Toward Precision Medicine. Clinical Pharmacology and Therapeutics, 2019, 106, 204-210.	2.3	24
72	Problems with the two stage analysis of crossover trials [letter; comment]. British Journal of Clinical Pharmacology, 1991, 32, 133-711.	1.1	22

#	ARTICLE	IF	CITATIONS
73	LETTER TO THE EDITOR: Testing for Individual and Population Equivalence Based on the Proportion of Similar Responses, by D. M. Rom and E. Hwang, <i>Statistics in Medicine</i> , 15, 1489-1505 (1996). <i>Statistics in Medicine</i> , 1997, 16, 1303-1305.	0.8	22
74	Comment on Gelman and Shalizi. <i>British Journal of Mathematical and Statistical Psychology</i> , 2013, 66, 65-67.	1.0	22
75	Various varying variances: The challenge of nuisance parameters to the practising biostatistician. <i>Statistical Methods in Medical Research</i> , 2015, 24, 403-419.	0.7	22
76	Lessons learned from IDeAl – 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 77.	1.2	22
77	Suspended judgment n-of-1 trials. <i>Contemporary Clinical Trials</i> , 1993, 14, 1-5.	2.0	21
78	Some issues in predicting patient recruitment in multi-centre clinical trials. <i>Statistics in Medicine</i> , 2013, 32, 5458-5468.	0.8	21
79	Planning and analysis of crossover trials in infertility. <i>Statistics in Medicine</i> , 2010, 29, 3203-3210.	0.8	20
80	R&D productivity rides again?. <i>Pharmaceutical Statistics</i> , 2015, 14, 1-3.	0.7	20
81	Maximum likelihood estimation of treatment effects for samples subject to regression to the mean. <i>Communications in Statistics - Theory and Methods</i> , 1989, 18, 3389-3406.	0.6	19
82	Examples of option values in drug development. <i>Pharmaceutical Statistics</i> , 2003, 2, 113-125.	0.7	18
83	Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee – adolescents’ melanoma as a paradigm. <i>Pharmaceutical Statistics</i> , 2014, 13, 211-213.	0.7	18
84	A note regarding “random effects”. <i>Statistics in Medicine</i> , 2014, 33, 2876-2877.	0.8	18
85	The statistical properties of RCTs and a proposal for shrinkage. <i>Statistics in Medicine</i> , 2021, 40, 6107-6117.	0.8	18
86	Turning a blind eye: Authors have blinkered view of blinding. <i>BMJ: British Medical Journal</i> , 2004, 328, 1135.3-1136.	2.4	18
87	In defence of analysis of covariance: A reply to Chambless and Roebuck. <i>Statistics in Medicine</i> , 1995, 14, 2283-2285.	0.8	17
88	Screening for breast cancer with mammography. <i>Lancet, The</i> , 2001, 358, 2165.	6.3	17
89	Lessons from TGN1412 and TARGET: implications for observational studies and meta-analysis. <i>Pharmaceutical Statistics</i> , 2008, 7, 294-301.	0.7	17
90	Creating a suite of macros for meta-analysis in SAS®: A case study in collaboration. <i>Statistics and Probability Letters</i> , 2011, 81, 842-851.	0.4	17

#	ARTICLE	IF	CITATIONS
91	Does evidence support the high expectations placed in precision medicine? A bibliographic review. F1000Research, 2018, 7, 30.	0.8	17
92	Clinical cross-over trials in phase I. Statistical Methods in Medical Research, 1999, 8, 263-278.	0.7	16
93	Reporting of cross-over clinical trials of analgesic treatments for chronic pain: Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks systematic review and recommendations. Pain, 2016, 157, 2544-2551.	2.0	16
94	Combining Outcome Measures: Statistical Power Is Irrelevant. Biometrics, 1989, 45, 1027.	0.8	14
95	An unreasonable prejudice against modelling?. Pharmaceutical Statistics, 2005, 4, 87-89.	0.7	14
96	Probabilistic index: an intuitive non-parametric approach to measuring the size of the treatment effects by L. Acion, J. J. Peterson, S. Temple and S. Arndt, Statistics in Medicine 2006;25(4):591-602. Statistics in Medicine, 2006, 25, 3944-3946.	0.8	14
97	Does evidence support the high expectations placed in precision medicine? A bibliographic review. F1000Research, 2018, 7, 30.	0.8	14
98	A random effects model for ordinal responses from a crossover trial. by F. Ezzet and J. Whitehead, . Statistics in Medicine, 1993, 12, 2147-2151.	0.8	13
99	Further Statistical Issues in Project Prioritization in the Pharmaceutical Industry. Drug Information Journal, 1998, 32, 253-259.	0.5	13
100	Bronchodilation of formoterol administered with budesonide: Device and formulation effects. Contemporary Clinical Trials, 2008, 29, 114-124.	0.8	13
101	U is for Unease: Reasons for Mistrusting Overlap Measures for Reporting Clinical Trials. Statistics in Biopharmaceutical Research, 2011, 3, 302-309.	0.6	13
102	Caution in interpretation needed. BMJ: British Medical Journal, 1995, 310, 667-667.	2.4	13
103	LETTER TO THE EDITOR: The case for cross-over trials in phase III by B. J. Jones and J. Lewis, Statistics in Medicine, 14, 1025-1038 (1995). , 1997, 16, 2021-2022.		12
104	Transposed Conditionals, Shrinkage, and Direct and Indirect Unbiasedness. Epidemiology, 2008, 19, 652-654.	1.2	12
105	Progression-seeking bias and rational optimism in research and development. Nature Reviews Drug Discovery, 2015, 14, 219-221.	21.5	12
106	Implementing Historical Controls in Oncology Trials. Oncologist, 2021, 26, e859-e862.	1.9	12
107	Misunderstanding publication bias: editors are not blameless after all. F1000Research, 2012, 1, 59.	0.8	12
108	Ten simple rules for good research practice. PLoS Computational Biology, 2022, 18, e1010139.	1.5	12

#	ARTICLE	IF	CITATIONS
109	“Equivalence is Different” – Some Comments on Therapeutic Equivalence. <i>Biometrical Journal</i> , 2005, 47, 104-107.	0.6	11
110	Drawbacks to Noninteger Scoring for Ordered Categorical Data. <i>Biometrics</i> , 2007, 63, 296-298.	0.8	11
111	A century of <i>T</i> -tests. <i>Significance</i> , 2008, 5, 37-39.	0.3	11
112	What does randomisation achieve?. <i>Evidence-Based Medicine</i> , 2012, 17, 1-2.	0.6	11
113	Statistical issues in first-in-human studies on BIA 102474: Neglected comparison of protocol against practice. <i>Pharmaceutical Statistics</i> , 2017, 16, 100-106.	0.7	11
114	Clustered allocation as a way of understanding historical controls: Components of variation and regulatory considerations. <i>Statistical Methods in Medical Research</i> , 2020, 29, 1960-1971.	0.7	11
115	Regression: A New Mode for an Old Meaning?. <i>American Statistician</i> , 1990, 44, 181.	0.9	11
116	Screening mammography re-evaluated. <i>Lancet</i> , The, 2000, 355, 750.	6.3	10
117	Epigenetics or ephemeral genetics?. <i>European Journal of Human Genetics</i> , 2006, 14, 1149-1149.	1.4	10
118	Being Efficient About Efficacy Estimation. <i>Statistics in Biopharmaceutical Research</i> , 2013, 5, 204-210.	0.6	10
119	Power is indeed irrelevant in interpreting completed studies. <i>BMJ</i> , The, 2002, 325, 1304.	3.0	10
120	Cross-over trials in drug development: theory and practice. <i>Journal of Statistical Planning and Inference</i> , 2001, 96, 29-40.	0.4	9
121	A Conversation with John Nelder. <i>Statistical Science</i> , 2003, 18, 118.	1.6	9
122	Mathematics Governess or Handmaiden?. <i>Journal of the Royal Statistical Society: Series D (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22</i>	0.2	8
123	Letters to the editor. <i>Annals of Allergy, Asthma and Immunology</i> , 2000, 84, 639.	0.5	8
124	Placebo Misconceptions. <i>American Journal of Bioethics</i> , 2009, 9, 53-54.	0.5	8
125	Treatment Effects in Multicenter Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1211.	3.8	8
126	Random main effects of treatment: A case study with a network meta-analysis. <i>Biometrical Journal</i> , 2019, 61, 379-390.	0.6	8

#	ARTICLE	IF	CITATIONS
127	Does evidence support the high expectations placed in precision medicine? A bibliographic review. F1000Research, 0, 7, 30.	0.8	8
128	Covariance analysis in generalized linear measurement error models. Statistics in Medicine, 1990, 9, 583-586.	0.8	7
129	Baseline distribution and conditional size. Journal of Biopharmaceutical Statistics, 1993, 3, 265-270.	0.4	7
130	Letter to the editor. Contemporary Clinical Trials, 2000, 21, 589-592.	2.0	7
131	Authorship of drug industry trials. Pharmaceutical Statistics, 2002, 1, 5-7.	0.7	7
132	Commentary on "Designs for dose" escalation trials with quantitative responses". Statistics in Medicine, 2009, 28, 3754-3758.	0.8	7
133	A note regarding meta-analysis of sequential trials with stopping for efficacy. Pharmaceutical Statistics, 2014, 13, 371-375.	0.7	7
134	Does evidence support the high expectations placed in precision medicine? A bibliographic review. F1000Research, 0, 7, 30.	0.8	7
135	Cross-over Trials. , 0, , 273-285.		7
136	A Note Concerning the Analysis of an Epidemic of Q Fever. International Journal of Epidemiology, 1988, 17, 891-893.	0.9	6
137	The analysis of the AB/BA cross-over trial in the medical literature. Pharmaceutical Statistics, 2004, 3, 123-131.	0.7	6
138	Misunderstandings regarding clinical cross-over trials. Statistics in Medicine, 2005, 24, 3675-3678.	0.8	6
139	Invalid inversion. Significance, 2013, 10, 40-42.	0.3	6
140	The outstanding scientist, R.A. Fisher: his views on eugenics and race. Heredity, 2021, 126, 565-576.	1.2	6
141	Determining the Sample Size. , 0, , 195-212.		6
142	Authors are also reviewers: problems in assigning cause for missing negative studies. F1000Research, 2013, 2, 17.	0.8	5
143	A Comment on Optimal Allocations for Bioequivalence Studies. Biometrics, 1999, 55, 1314-1315.	0.8	4
144	Editorial: Pharmaceuticals, patents and competition-some statistical issues. Journal of the Royal Statistical Society Series A: Statistics in Society, 2003, 166, 271-274.	0.6	4

#	ARTICLE	IF	CITATIONS
145	The t-test tool. Significance, 2008, 5, 40-41.	0.3	4
146	The design and analysis of vaccine trials for COVID-19 for the purpose of estimating efficacy. Pharmaceutical Statistics, 2022, 21, 790-807.	0.7	4
147	Lost opportunities for statistics. Pharmaceutical Statistics, 2003, 2, 3-4.	0.7	3
148	An Early "Atkins' Diet" RA Fisher Analyses a Medical "Experiment". Biometrical Journal, 2006, 48, 193-204.	0.6	3
149	Contribution to the discussion of "A critical evaluation of the current <i>p</i> -value controversy". Biometrical Journal, 2017, 59, 892-894.	0.6	3
150	Childhood asthma exacerbations and ADRB2 polymorphism: Caution is needed. Journal of Allergy and Clinical Immunology, 2018, 141, 1954-1955.	1.5	3
151	Ethics of clinical trials from bayesian perspective: Society's role is important. BMJ: British Medical Journal, 2003, 326, 1456-b-1457.	2.4	3
152	JOHN NELDER: FROM GENERAL BALANCE TO GENERALISED MODELS (BOTH LINEAR AND HIERARCHICAL). , 2004, , 1-11.		3
153	Regression to the mean and crossover trials revisited. Statistics in Medicine, 1994, 13, 1181-1186.	0.8	2
154	A Comment on Interim Analyses in Crossover Trials. Biometrics, 1996, 52, 1515.	0.8	2
155	Baseline balance and conditional size: a reply to overall Et al. Journal of Biopharmaceutical Statistics, 1996, 6, 201-210.	0.4	2
156	Bitter Pills and Puffed Trials. PLoS Medicine, 2005, 2, e219.	3.9	2
157	Sharp tongues and bitter pills. Significance, 2006, 3, 123-125.	0.3	2
158	Safety first?. Significance, 2007, 4, 79-80.	0.3	2
159	A Brief Note Regarding Randomization. Perspectives in Biology and Medicine, 2013, 56, 452-453.	0.3	2
160	One-Sided and Two-Sided Tests and other Issues to Do with Significance and P-Values. , 0, , 183-193.		2
161	Competing interests. BMJ: British Medical Journal, 2003, 326, 883-883.	2.4	2
162	JAMA's policy does not go far enough. BMJ: British Medical Journal, 2006, 332, 305.2.	2.4	2

#	ARTICLE	IF	CITATIONS
163	Crossover Design. , 2010, , 380-385.		2
164	Sober view of AIDS. Nature, 1987, 328, 10-10.	13.7	1
165	Regression toward the mean in 2 \bar{X} - 2 crossover designs with baseline measurements. Statistics in Medicine, 1993, 12, 1086-1087.	0.8	1
166	A Comment on CHI, E. M., 1992: Analysis of cross-over trials when within-subject errors follow an AR(1) process. Biom. J. 34, 359-365. Biometrical Journal, 1994, 36, 125-128.	0.6	1
167	Preface. , 1999, 18, 1739-1739.		1
168	Foreword: A blue plaque for Fisher. Journal of the Royal Statistical Society: Series D (the Statistician), 2003, 52, 297-298.	0.2	1
169	When is a drug not a drug?. Significance, 2004, 1, 159-161.	0.3	1
170	Meta-Analysis Combining 2 Previously Reported Trials on Respiratory Distress Syndrome in Neonates. Pediatrics, 2007, 120, 1224-1225.	1.0	1
171	Editorial/Letters. Significance, 2008, 5, 92-93.	0.3	1
172	Significant errors. Lancet, The, 2010, 376, 1390-1391.	6.3	1
173	Bad karma. Medical Writing, 2013, 22, 252-255.	0.0	1
174	A Chronicle of Permutation Statistical Methods: 1920-2000, and Beyond, by K J Berry, J E Johnston, and P J W Mielke. Bulletin of the British Society for the History of Mathematics, 2016, 31, 155-156.	0.1	1
175	Some controversies in planning and analysing multi-centre trials. , 1998, 17, 1753.		1
176	Some controversies in planning and analysing multi-centre trials. Statistics in Medicine, 1998, 17, 1753-1765.	0.8	1
177	Robust and realistic approaches to carry-over. Statistics in Medicine, 1998, 17, 2849-2864.	0.8	1
178	Investigating underlying risk as a source of heterogeneity in meta-analysis by S. G. Thompson, T. C. Smith and S. J. Sharp, Statistics in Medicine, 16, 2741-2758 (1997). Statistics in Medicine, 1999, 18, 110-115.	0.8	1
179	Design and Interpretation of Clinical Trials as Seen by a Statistician. , 0, , 27-42.		1
180	Misunderstanding publication bias: editors are not blameless after all. F1000Research, 0, , .	0.8	1

#	ARTICLE	IF	CITATIONS
181	Giving and taking: ethical treatment assignment in controlled trials. Journal of the Royal Society of Medicine, 2021, 114, 525-530.	1.1	1
182	The Work of the Pharmaceutical Statistician. , 0, , 55-66.		1
183	Empirical studies of balance do not justify a requirement for 1,000 patients per trial. Journal of Clinical Epidemiology, 2022, 148, 184-188.	2.4	1
184	LETTER TO THE EDITOR INCLUDING AUTHOR'S REPLY: A PERSONAL VIEW OF SOME CONTROVERSIES IN ALLOCATING TREATMENT TO PATIENTS IN CLINICAL TRIALS by Stephen Senn, Statistics in Medicine, 14, 2661-2674 (1995). , 1996, 15, 113-116.		0
185	The Unpleasant Placebo?. Chance, 2002, 15, 27-29.	0.1	0
186	Analysis: Repeated Measures in Clinical Trials: Simple Strategies for Analysis Using Summary Measures. , 2005, , 379-395.		0
187	Intention to Treat, Missing Data and Related Matters. , 0, , 165-181.		0
188	Statisticians and evidence " mote and beam. Pharmaceutical Statistics, 2008, 7, 155-157.	0.7	0
189	Authors' Rejoinder to Commentaries on "Measurement in clinical trials: A neglected issue for statisticians?"™. Statistics in Medicine, 2009, 28, 3223-3225.	0.8	0
190	BMJ tackles FDA's mote in eye while ignoring own beam. BMJ: British Medical Journal, 2011, 343, d5614-d5614.	2.4	0
191	A note regarding Lee's checks for minimum numbers of subjects where relative risks have been calculated. Statistics in Medicine, 2014, 33, 4135-4138.	0.8	0
192	Cushny and Peebles, optical isomers and the birth of modern statistics. Journal of the Royal Society of Medicine, 2017, 110, 501-502.	1.1	0
193	Statistical Analysis Plans for Clinical Trials"Reply. JAMA - Journal of the American Medical Association, 2018, 319, 1938.	3.8	0
194	John Ashworth Nelder. 8 October 1924"7 August 2010. Biographical Memoirs of Fellows of the Royal Society, 2019, 67, 307-326.	0.1	0
195	Stephen Senn"™s contribution to the Discussion of "Testing by betting: A strategy for statistical and scientific communication"™ by Glenn Shafer. Journal of the Royal Statistical Society Series A: Statistics in Society, 2021, 184, 459-460.	0.6	0
196	<i>P</i>-Values. , 2010, , 940-948.		0
197	Adverse Gastrointestinal Effects of Brief Use of Full Strength, OTC Aspirin in Randomized Clinical Trials: A Meta-Analysis. American Journal of Gastroenterology, 2010, 105, S393.	0.2	0
198	Modelling in Radioactive Waste Disposal. , 0, , 173-185.		0

#	ARTICLE	IF	CITATIONS
199	P-Values. , 2012, , 940-948.		0
200	Crossover Design. , 2012, , 380-385.		0
201	Multiplicity. , 0, , 149-164.		0
202	Multicentre Trials. , 0, , 213-233.		0
203	Active Control Equivalence Studies. , 0, , 235-250.		0
204	n-of-1 Trials. , 0, , 287-294.		0
205	Sequential Trials. , 0, , 295-315.		0
206	A Brief and Superficial History of Statistics for Drug Developers. , 0, , 9-25.		0
207	Dose-Finding. , 0, , 317-336.		0
208	Concerning Pharmacokinetics and Pharmacodynamics. , 0, , 337-360.		0
209	Bioequivalence Studies. , 0, , 361-381.		0
210	Safety Data, Harms, Drug Monitoring and Pharmaco-Epidemiology. , 0, , 383-404.		0
211	Pharmaco-Economics and Portfolio Management. , 0, , 405-431.		0
212	Concerning Pharmacogenetics, Pharmacogenomics and Related Matters. , 0, , 433-452.		0
213	Probability, Bayes,P-Values, Tests of Hypotheses and Confidence Intervals. , 0, , 43-53.		0
214	Allocating Treatments to Patients in Clinical Trials. , 0, , 67-93.		0
215	The Measurement of Treatment Effects. , 0, , 113-131.		0
216	Demographic Subgroups: Representation and Analysis. , 0, , 133-148.		0

#	ARTICLE	IF	CITATIONS
217	Statistics in Practice. , 0, , 499-500.		0
218	<scp>Viewpoint</scp> : Do not resurrect the two-stage procedure. Pharmaceutical Statistics, 2022, 21, 808-814.	0.7	0